Explore more publications!
Harrisburg Wellness Reporter
Got News to Share?

Harrisburg Wellness Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Press releases published on April 22, 2026

VAR Checks Drive £10,000 Donation as Bally Bet Turns Match Moments into Life-Saving Reminders​
Apr. 22, 2026

VAR Checks Drive £10,000 Donation as Bally Bet Turns Match Moments into Life-Saving Reminders​

Indeterminate EIN Presswire
Aethl Bio and Pure Source Enter Collaboration to Advance Proprietary Hydrogel Product Line
Apr. 22, 2026

Aethl Bio and Pure Source Enter Collaboration to Advance Proprietary Hydrogel Product Line

Indeterminate EIN Presswire
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Apr. 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Indeterminate GlobeNewswire
HMP Global’s Dermatology Co-Scientific Director Dr. Alice Gottlieb Elected AAD Vice President
Apr. 22, 2026

HMP Global’s Dermatology Co-Scientific Director Dr. Alice Gottlieb Elected AAD Vice President

Indeterminate EIN Presswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage
Apr. 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Indeterminate GlobeNewswire
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Apr. 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire
Sight Sciences Announces the Release of its Sustainability Report
Apr. 22, 2026

Sight Sciences Announces the Release of its Sustainability Report

Indeterminate GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Apr. 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Altimmune Announces Proposed Underwritten Public Offering of Securities
Apr. 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

Indeterminate GlobeNewswire
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
Apr. 22, 2026

Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5

Indeterminate GlobeNewswire
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Apr. 22, 2026

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Indeterminate GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Apr. 22, 2026

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

Indeterminate GlobeNewswire
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
Apr. 22, 2026

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

Indeterminate GlobeNewswire
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
Apr. 22, 2026

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

Indeterminate GlobeNewswire
Abivax to Present Data on Obefazimod at Digestive Disease Week®
Apr. 22, 2026

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Indeterminate GlobeNewswire
SkinHealth Systems Inc. Appoints Three New Independent Directors to Board
Apr. 22, 2026

SkinHealth Systems Inc. Appoints Three New Independent Directors to Board

Indeterminate GlobeNewswire
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr. 22, 2026

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions